Is NVCR overvalued right now?
A stock is overvalued when its market price sits above a reasonable fair value range. Use the live snapshot on this page for NVCR, then validate with fundamentals and peer multiples.
NovoCure Limited (NVCR) is currently Undervalued by 596.66%
Instant valuation answer
NovoCure Limited (NVCR) appears undervalued by approximately 596.66% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.
- Upside (live) 596.66% (from live valuation API)
- Confidence (live) 9.5/10 (Very High)
Confidence Score is based on the magnitude of upside or downside vs intrinsic value.
Fair value estimate
Unlock fair valueCurrent price
$17.72
Stock valuation checker
Search our company database (same as the site header). Choose a result or type a ticker and press Check valuation.
Explore Our Valuation Calculators
Why is NovoCure Limited overvalued or undervalued?
Intrinsic value work anchors NovoCure Limited on owner earnings and balance-sheet capacity; the current quote trades above that anchor, which frames the stock as relatively rich on a fundamentals-first view.
Versus historical valuation bands, NVCR is closer to the upper end of where this business has traded when profitability and growth were comparable—useful context before reading any single headline multiple.
Forward market expectations are elevated: the price requires heroic assumptions to converge with our fair-value zone, but sector peers and macro rates still deserve a quick sanity check on the company page.
Key metrics
- P/E ratio
- 39.1x
- Revenue growth (TTM y/y)
- 12%
- Profit margin
- 30.2%
- Fair value (model)
- Unlock
Frequently asked questions — NVCR
What is NovoCure Limited's intrinsic value?
Our DCF, P/E Multiple, and P/S Multiple models estimate whether NVCR trades above or below fair value. At $17.72, NovoCure Limited currently looks undervalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.
How is NovoCure Limited's intrinsic value calculated?
Tickerplace calculates NVCR's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.
Is NVCR undervalued right now?
Based on our 2026 valuation models, NovoCure Limited (NVCR) appears undervalued at $17.72 with about 596.7% upside to fair value. Treat this as a screen—verify fundamentals on the company profile.
Related companies — valuation
Peers for NVCR: open their overvalued / undervalued view.